<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>2026 Prices for Drugs That Are Subject to Negotiations | Khanh's feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nytimes.com/2024/08/15/us/politics/drug-prices-medicare-negotiations.html">Original</a>
    <h1>2026 Prices for Drugs That Are Subject to Negotiations</h1>
    
    <div id="readability-page-1" class="page"><div><p>The Biden administration on Thursday <a href="https://www.nytimes.com/2024/08/15/us/politics/us-to-announce-prices-for-first-drugs-picked-for-medicare-negotiations.html" title="">announced the results</a> of negotiations between Medicare and pharmaceutical companies over the prices of 10 costly or common medications. The new prices, which will take effect in 2026, are the maximum Medicare Part D plans and patients will pay for a one-month supply.</p><p>1. <strong>Eliquis</strong>, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231</p><p>2. <strong>Jardiance</strong>, for diabetes, heart failure and chronic kidney disease, from Boehringer Ingelheim and Eli Lilly, $197</p><p>3. <strong>Xarelto</strong>,<strong> </strong>for preventing strokes and blood clots, from Johnson &amp; Johnson, $197</p><p>4. <strong>Januvia</strong>, for diabetes, from Merck, $113</p><p>5. <strong>Farxiga</strong>, for diabetes, heart failure and chronic kidney disease, from AstraZeneca $178</p><p>6. <strong>Entresto</strong>, for heart failure, from Novartis, $295</p><p>7. <strong>Enbrel</strong>, for autoimmune conditions, from Amgen, $2,355</p><p>8. <strong>Imbruvica</strong>, for blood cancers, from AbbVie and Johnson &amp; Johnson, $9,319</p><p>9. <strong>Stelara</strong>, for autoimmune conditions, from Johnson &amp; Johnson, $4,695</p><p>10. <strong>Fiasp </strong>and<strong> NovoLog </strong>insulin products, for diabetes, from Novo Nordisk, $119</p></div></div>
  </body>
</html>
